Hepatitis and its complications

5,688 views 62 slides May 15, 2015
Slide 1
Slide 1 of 62
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30
Slide 31
31
Slide 32
32
Slide 33
33
Slide 34
34
Slide 35
35
Slide 36
36
Slide 37
37
Slide 38
38
Slide 39
39
Slide 40
40
Slide 41
41
Slide 42
42
Slide 43
43
Slide 44
44
Slide 45
45
Slide 46
46
Slide 47
47
Slide 48
48
Slide 49
49
Slide 50
50
Slide 51
51
Slide 52
52
Slide 53
53
Slide 54
54
Slide 55
55
Slide 56
56
Slide 57
57
Slide 58
58
Slide 59
59
Slide 60
60
Slide 61
61
Slide 62
62

About This Presentation

Hepatitis and its complications


Slide Content

HEPATITIS AND ITS COMPLICATIONS PRESENTERS: OTAALO BRIAN BYONANUWE SIMON

Outline Definition Classification Clinical features Specific causes of hepatitis Hepatitis B & Complications

Hepatitis Defn - inflammation of the liver Classification Duration : acute hepatitis vs chronic hepatitis Aetiology : Viral, drug induced, autoimmune

Causes Acute hepatitis Viral hepatitis Non - viral infection Alcohol Toxins Drugs Autoimmune Chronic hepatitis Viral hepatitis Alcohol Drugs Non-alcoholic steatohepatitis Autoimmune

Clinical features Acute hepatitis F atigue , anorexia, nausea, and vomiting Jaundice Severe cases may progress to acute liver failure

Cont … Chronic hepatitis Peripheral stigmata of chronic liver disease clubbing, leukonychia , palmar erythema, D upuytren’s contracture Paucity of axillary or pubic hair Spider naevi , jaundice ,parotic enlargement Gynaecomastia Ascites Testicular atrophy

Viral Hepatitis

Hepatitis A virus (HAV) Spread by fecal-oral route Incubation: 2-6wks Symptoms Prodomal - fever, malaise, anorexia, nausea, arthralgia Jaundice +/- hepatomegaly, splenomegaly Tests- AST & ALT rise 22-40 days after exposure - IgM rises after day 25, IgG remains detectable for life Treatment- supportive Prevention- immunization Prognosis- usually selflimiting , chronic liver disease doesn’t occur

Hepatitis C virus (HCV) Caused by RNA flavirus Spread through blood Risk factors IV drug misuse (95% in UK) Needle stick injury (3%) Vertical transmission (3%) Iatrogenic parenteral transmission

HCV cont … Clinical presentation Early infection is often mild/ asymptomatic i n asymptomatic pple , its usually identified when screened for Patients are usually identified with chronic liver disease 80% develop chronic inf , 20-30% progress to cirrhosis Tests Anti-HCV antibodies Comfirmed by HCV RNA in an antibody positive person

HCV cont … Treatment Aim is to eradicate infection Combination therapy of PEGylated interferon alpha & ribavirin Rivabirin – given as an oral drug -main side effects (S.Es) – hemolytic anaemia & teratogenicity PEGinterferon alpha – give subcutaneously once everywk S.Es- flu like symptoms, irritability & depression Liver transplant- in complications of cirrhosis

Hepatitis D virus (HDV) Incomplete RNA virus Only exists with HBV, therefore spread with HBV Signs : increased risk of acute hepatic failure and cirrhosis Tests: Anti-D antibody

Drug Induced Hepatitis The liver is the primary site of drug metabolism Risk Factors Occupational xposure , herbs Common drugs Paracetamol overdose Pyrazinzmide,Isoniazid , rifampicin AZT, NVP Halothane Treatment : withdraw offending drug

Autoimmune Hepatitis(AIH) Liver disease characterized by suppressor T cell defects with autoantibodies directed against hepatocyte surface antigens Predominantly affects women, in their 2 nd & 3 rd decades classification Type I- affects adults or children(bi modial distributuion ) - Anti smooth muscle antibodies(ASMA) + ve in 80% - antinuclear antibodies (ANA) + ve in 10 - Hypergammaglobulinaemia ( IgG )

AIH cont ……. Type II – Affects mainly girls & young women - more commonly progresses to cirrhosis - anti liver/kidney microsomal type 1 (LKM1) antibodies Type III – affects adults & clinically distinguishable from type1 - antibodies against soluble liver antigen or liver – pancrease Ag Clinical Features 25% present with acute hepatitis & signs of autoimmune disease - fever,malaise , urticarial rash, glomerulonephritis

Cont.. Signs of chronic liver disease Complications- cirrhosis Tests Abnormal LFT ( increased AST,ALT,birilubin,ALP ) Hyperalbuminaemia ( esp IgG ) + ve autoantibodies (ANA,SMA, LKM1 or SLA) Anaemia , reduced WCC & platelets – hypersplenism Liver biopsy

Cont.. Diagnosis depends on excluding other diseases Management Immunosuppression therapy - prednisolone 30mg/d for a month, decrease by 5mg a month Maintanance dose 5-10mg/d for a month Azathioprine (50-100mg/d) may b used as asteroid sparing agent Liver transplant- in decompensated cirrhosis - failure to respond to medical therapy Prognosis- 10yr survival approx. 80%

The virus Small(42nm), double stranded, DNA virus Also called Dane particle Hepadnaviridae Infects only humans Genetic variations A-H Rx implications Global distribution

Double shelled, inner core and outer envelope

Transmission Vertical transmission(90%), from mother to child in the perinatal period, is the most common cause of infection world-wide and carries the highest risk . Others; Injection drug use Infected unscreened blood products Tattoos/acupuncture needles Sexual (homosexual and heterosexual)

Risk groups Iv drug users and their sexual partners Health workers Hemophiliacs and their cares The sexualy promiscuous

Natural hx Predominantly affect hepatocytes Causes both acute and chronic disease Incubation period 1-6mts There’s an initial immunitolerant phase An immunological torelance then occurs with elvn in hep transaminases, liver damage Cirrhosis if the response sustained over many yrs

M echanism Liver injury believed to be immunologically mediated Mediated by cytotoxic t cells Specific cytokines produced by the T cells These damage hepatocytes

C /features: Acute infn Often asymptomatic Non specific symptoms eg fatigue, anorexia, nausea, abd pain, low grade fevers Typically lasts 2-4mts Infants, cn <5yrs and iss adults more likely asymptomatic In aduots with healthy immune system; ~95% self ltd <5% adults progress to to chronic infection A small no (1%)develop AHF, may die or require urgent liver transplant.

C /f: chronic inf Considered chronic if >6/12 Risk inversely related to age, abt 90% of infected infant, 30% <5YRS, <5% older pple NB; a serum sickness-like immunological syndrome may be seen. urticaria or a maculopapular rash polyarthritis affecting small joints occurring in up to 25% of cases in the prodromal period . Extrahepatic immune complex-mediated conditions such as an arteritis or glomerulonephritis are occasionally seen

Dx Serology- HBsAg , HBsAb , HBcAb . LFTs Viral load/HBV PCR Monitoring response to therapy Identifying patients with pre coremutants Specific genotypes can be identified-B&C more aggressive!

Interpretation-serology results Immune due to natura infn Acutely infected Chronically infected Hepb vaccination HBsAg neg Anti HBc pos Anti HBs pos HBsAg pos Anti HBc pos Anti HBcIgM pos ANTI HBs neg HBsAg pos Anti HBc pos Anti HBcIgG pos Anti HBs neg HBsAg neg HBc Ab neg Anti HBs pos

Rx; acute Supportive Avoid alcohol

Who shd be treated? Chronic HBV infection: HBsAg + > 6 months Evidence of virus replication: serum HBV DNA >10 5 copies/ml Evidence of liver damage: elevated ALT and/or chronic hepatitis on biopsy

Rx; chronic Indicatation : high viral load in presence of active hep as may be demonstrated by: Elevated transaminases and/or Histological evidence of inflammn Goals: Reduce infllammn Prevent liver failure Reduce risk of cirrhosis and complications by suppressing HBV replication

Inj. Pegylated interferon alfa 2a 180mcg/ wk X 48/52 Or other antiviral(oral) e.g Adevofir 10mg/day Lamivudine 100mg/day Tenofovir 300mg/day Others recommended telbivudine , entecavir . Add 2 nd antiviral if HBV DNA stil detactable wthin 6-12mts Monitor renal function

C omplications Fulminant HF Cirrhosis and its complications Extrahepatic dse Etc

CIRRHOSIS end stage of chronic liver disease characterised by: destruction of the normal hepatic archtecture by fibrous septa that encompass regenerative nodules of hepatocytes The liver architecture is diffusely abnormal this interferes with liver blood flow and function. This derangement produces the clinical features of portal hypertension and impaired liver cell function.

There’s… Parenchymal injury and consequent fibrosis are diffuse, extending throughout the liver . Irreversible fibrosis Nodularity Vascular architecture is reorganised by the parenchymal damage and scarring  formation of abnormal interconnections between vascular inflow and hepatic vein outflow channels. 

C auses Alcohol Chronic viral hepatitis (B or C) Non-alcoholic fatty liver disease Immune Primary sclerosing cholangitis Autoimmune liver disease Biliary Primary biliary cirrhosis Cystic fibrosis Genetic Haemochromatosis α1- antitrypsin deficiency Wilson's disease Cryptogenic (unknown

Pathogenesis Chronic injury to the liver---inflammation--necrosis and, eventually, fibrosis. Fibrosis initiated by activation of stellate cells. Kupffer cells seem to have a role in their activation, but hepatocytes and other cells are probably involved. Stellate cells are activated by many cytokines.

Cont… In the early stage of activation the stellate cells become swollen with upregulation of receptors for proliferative and fibrogenic cytokines, such as PDGF, and possibly transforming growth factor β1 (TGF-β1). In the space of Disse , the normal matrix is replaced by collagens, predominantly types 1 and 3, and fibronectin. Subendothelial fibrosis leads to loss of the endothelial fenestrations, and this impairs liver function. increase in tissue inhibitors of metalloproteinases (TIMPs), wc inhibit Collagenases (matrix metalloproteinases , MMP) that wd o/wise degrade this collagen.

Two types of cirrhosis have been described Micronodular cirrhosis. Xterised by small nodules, abt 1mm in diameter( less than 3 mm) in size and the liver is involved uniformly. Often in alcohol cirhhosis , biliaryb tract dse Macronodular cirrhosis. Large nodules are of variable size. often seen following previous hepatitis, such as HBV infection. A mixed picture with small and large nodules is sometimes seen.

Clinical features vary greatly may be entirely asymptomatic; in life it may be found incidentally at surgery or may be associated with minimal features such as isolated hepatomegaly. Frequent complaints include weakness, fatigue, muscle cramps, weight loss and non-specific digestive symptoms such as anorexia, nausea, vomiting and upper abdominal discomfort. Otherwise , clinical features are due mainly to hepatic insufficiency and portal hypertension

Cont… Hepatomegaly (although liver may also be small) Jaundice Ascites Circulatory changes Spider telangiectasia, palmar erythema, cyanosis Endocrine changes Loss of libido, hair loss Men: gynaecomastia , testicular atrophy, impotence Women: breast atrophy, irregular menses, amenorrhoea

Cont… Haemorrhagic tendency Bruises, purpura , epistaxis, menorrhagia Portal hypertension Splenomegaly, collateral vessels, variceal bleeding, fetor hepaticus Hepatic ( portosystemic ) encephalopathy Other features Pigmentation, digital clubbing

Investigations Labs LFTs- normal, or increasd biliru , AST, ALT, ALK PHOSPH AND GGT. LATER with loss of synthetic fuction , look for decreased albn . Decreased WCC, and platelates indicatete hypersplensm Find the cause; ferritin, iron/total ironbinding capacity, hepatitis serology, immunoglobulins, ceruloplasmin , etc U /s may show small livr or hepatomega , splenom , ascites, focal liver lesions etc. Ascitic tap—MC+S, NEUTRO>250/mm3 indicate SBP. Liver bx -----c onfirms dx.

C omplications VARICES Varices Anemia Renal failure Infection Coagulopathy Encephalopathy Sepsis

M x General measures Nutritional counsellg Alcohol abstinence Regular u/s +/- alfa fetoprotein 3-6mts. Manage complications

PORTAL HYPERTENSION C haracterised by prolonged elevation of the portal venous pressure (normally 2-5 mmHg). Patients developing clinical features or complications of portal hypertension usually have portal venous pressures above 12 mmHg. Can be classified according to the site of obstruction: prehepatic intrahepatic - due to distortion of the liver architecture, can be presinusoidal (e.g. in schistosomiasis ) or postsinusoidal (e.g. in cirrhosis )

Cont… posthepatic - due to venous blockage outside the liver (rare). As portal pressure rises above12 mmHg, the compliant venous system dilates and collaterals occur within the systemic venous system. Main sites of collaterals are at gastro- oesophageal junction and rectum.

Causes Prehepatic : -obstructive thrombosis, narrowing of portal vein before it branches within the liver. - massive splenomegally may shunt excessive blood into the splenic vein .   Posthepatic causes: -         severe right-sided heart failure -         constrictive pericarditis -         hepatic vein outflow obstruction   Intrahepatic causes: -         cirrhosis (most dominant) -         schistosomiasis -         massive fatty change -         diffuse fibrosis eg . Sarcoidosis. eg granulomatous disease -         milliary tuberculosis.

Pathophysio… Portal hypertension in cirrhosis results from - increased resistance to portal flow at the level of the sinusoids. -   compression of central veins by perivenular fibrosis This increased resistance leads to portal hypertension and opening of portosystemic anastomoses

Consequences Ascites Formation of porto -systemic shunts Congestive splenomegaly Congestive gastropathy Hepatic encephalopathy

VARICEAL BEEDING important to appreciate the portal systemic shunts With the rise in portal system pressure, bypasses develop wherever systemic and portal circulation share common capillary beds: Veins around and within rectum ( hemorrhoids ) Superior rectal vein Vs middle and inferior rectal veins ii. Cardio-esophageal junction ( esophago -gastric varices ) Left gastric Vs azygos iii. Retroperitoneum and falciform ligament of the liver involving the periumbilical and abnominal wall collaterals)  caput medusa Paraumbilical Vs left branch of portal vein

Important… ~ 90% of cirrhosis patients develop esophageal varices ~1/3 bleed Bleeding more likely in Large varices Red signs Severe liver dse Drugs capable of causing mucosal erosions eg NSAIDS better avoided. can ppt bleedg .

Mx : active bleeding, prevent rebleeding , prophylaxix to prevent 1st hemorrhage.

Cont… Acute variceal bleeding ABC, iv access, samples gping&xmatch,hb , pt / INRetc , resuscitate-restore circuln wth blood and plasma. Urgent endoscopy , even in known case; 20% not varices but other lesions-acute gastric erosions Local measures-used to control acute v. bleedg Endoscopic Band ligation or sclerotherapy- most widely used initial Rx, stops variceal bleeding in 80% .

Cont… Balloon tamponade Oesophageal transection Pharmacological treatment Terlipressin is the current drug of choice and releases the vasoconstrictor, vasopressin, over several hours in amounts sufficient to reduce the portal pressure without producing systemic effects. dose : 2 mg i.v. 6-hrly until bleeding stops, then 1 mg 6-hrlyxfurther 24 hrs.

Cont… Octreotide , the synthetic form of somatostatin, 50 μg iv, followed by an infusion of 50 μg hourly. TIPSS and shunt surgery( transjugular intrahepatic portosystemic stent shunting ) used for acute bleeding not responding to sclerotherapy or banding. Asscociated high (50%) mortality or more, now virtually never used for treating active variceal bleeding.

Prevention of recurrent bleeding Recurrent bleeding is the rule rather than the exception in patients who have previously bled from oesophageal varices, and treatment to prevent this is needed. Band ligation Varices occluded with a tight rubber band. The occluded varix subsequently sloughs with variceal obliteration. repeated every 1-2 weeks until the varices are obliterated. Regular follow-up endoscopy required to identify and treat any recurrence of varices. generally more effective than sclerotherapy, has fewer side-effects and is now the treatment of choice.

Cont… Sclerotherapy varices are injected with a sclerosing agent, been largely abandoned in pref to banding ligation. !transient chest or abd pain, fever, dysphagia, occasionally oes . perforation. Oesophageal strictures may also develop.

Cont… TIPSS S tent placed between the portal vein and the hepatic vein in the liver to provide a portosystemic shunt and therefore reduce portal pressure.

Cont… β-blockers Propranolol (80-160 mg/day) or nadolol Reduces portal venous pressure in portal hypertension and have been used to prevent recurrent variceal bleeding

CONGESTIVE GASTROPATHY chronic gastric congestion due to Long-standing portal hypertension Endoscopy-multiple areas of punctate erythema. Rarely , similar lesions occur more distally in the GIT. may become eroded, causing bleeding from multiple sites. Acute bleeding can occur, but repeated minor bleeding causing iron-deficiency anaemia is more common. Anaemia may be prevented by oral iron supplements. Reduction of the portal pressure using propranolol 80-160 mg/day is the best initial Rx. If ineffective , TIPSS can be undertaken.

…….end